200 related articles for article (PubMed ID: 31415381)
21. 240-week entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C.
Xu JH; Fan YN; Yu YY; Si CW; Zeng Z; Xu ZN; Li J; Mao Q; Zhang DZ; Tang H; Sheng JF; Chen XY; Ning Q; Shi GF; Xie Q; Zhang XQ; Dai J
J Viral Hepat; 2022 Oct; 29(10):862-867. PubMed ID: 35737855
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
[TBL] [Abstract][Full Text] [Related]
23. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
Berg T; Simon KG; Mauss S; Schott E; Heyne R; Klass DM; Eisenbach C; Welzel TM; Zachoval R; Felten G; Schulze-Zur-Wiesch J; Cornberg M; Op den Brouw ML; Jump B; Reiser H; Gallo L; Warger T; Petersen J;
J Hepatol; 2017 Nov; 67(5):918-924. PubMed ID: 28736139
[TBL] [Abstract][Full Text] [Related]
24. Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study.
Batirel A; Guclu E; Arslan F; Kocak F; Karabay O; Ozer S; Turanli M; Mert A
Int J Infect Dis; 2014 Nov; 28():153-9. PubMed ID: 25286184
[TBL] [Abstract][Full Text] [Related]
25. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
Lampertico P; Buti M; Fung S; Ahn SH; Chuang WL; Tak WY; Ramji A; Chen CY; Tam E; Bae H; Ma X; Flaherty JF; Gaggar A; Lau A; Liu Y; Wu G; Suri V; Tan SK; Subramanian GM; Trinh H; Yoon SK; Agarwal K; Lim YS; Chan HLY
Lancet Gastroenterol Hepatol; 2020 May; 5(5):441-453. PubMed ID: 32087795
[TBL] [Abstract][Full Text] [Related]
26. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
[TBL] [Abstract][Full Text] [Related]
27. Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough?
Liang X; Xie Q; Shang J; Tang H; Xu M; Meng Q; Zhang J; Gao P; Sheng J; Wang H; Jia J; Wang G; Wu S; Ping J; Hou J
J Gastroenterol Hepatol; 2022 Mar; 37(3):471-479. PubMed ID: 34894002
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany.
Petersen J; Heyne R; Mauss S; Schlaak J; Schiffelholz W; Eisenbach C; Hartmann H; Wiese M; Boeker K; Loehr HF; John C; Leuschner M; Trautwein C; Felten G; Trein A; Krause W; Ruppert S; Warger T; Hueppe D
Dig Dis Sci; 2016 Oct; 61(10):3061-3071. PubMed ID: 26576555
[TBL] [Abstract][Full Text] [Related]
29. Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen.
Jourdain G; Ngo-Giang-Huong N; Cressey TR; Hua L; Harrison L; Tierney C; Salvadori N; Decker L; Traisathit P; Sirirungsi W; Khamduang W; Bowonwatanuwong C; Puthanakit T; Siberry GK; Watts DH; Murphy TV; Achalapong J; Hongsiriwon S; Klinbuayaem V; Thongsawat S; Chung RT; Pol S; Chotivanich N
BMC Infect Dis; 2016 Aug; 16():393. PubMed ID: 27506549
[TBL] [Abstract][Full Text] [Related]
30. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
Liu Y; Corsa AC; Buti M; Cathcart AL; Flaherty JF; Miller MD; Kitrinos KM; Marcellin P; Gane EJ
J Viral Hepat; 2017 Jan; 24(1):68-74. PubMed ID: 27658343
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy of 48-week tenofovir disoproxil fumarate therapy in patients who were unresponsive to nucleoside-analogue treatments].
Huang M; Li X; Wu Y; Tao L; Jie Y; Li X; Shi H; Lin G; Yang F; Ao Y; Pang Y; Zhang M; Chong Y
Zhonghua Gan Zang Bing Za Zhi; 2014 Apr; 22(4):266-71. PubMed ID: 25173224
[TBL] [Abstract][Full Text] [Related]
32. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
[TBL] [Abstract][Full Text] [Related]
33. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
Bazinet M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Krawczyk A; Vaillant A
Gastroenterology; 2020 Jun; 158(8):2180-2194. PubMed ID: 32147484
[TBL] [Abstract][Full Text] [Related]
34. Efficacy Comparison of Tenofovir and Entecavir in HBeAg-Positive Chronic Hepatitis B Patients with High HBV DNA.
Shi H; Huang M; Lin G; Li X; Wu Y; Jie Y; Chong Y
Biomed Res Int; 2016; 2016():6725073. PubMed ID: 27034945
[TBL] [Abstract][Full Text] [Related]
35. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
[TBL] [Abstract][Full Text] [Related]
36. Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.
Boni C; Janssen HLA; Rossi M; Yoon SK; Vecchi A; Barili V; Yoshida EM; Trinh H; Rodell TC; Laccabue D; Alfieri A; Brillo F; Fisicaro P; Acerbi G; Pedrazzi G; Andreone P; Cursaro C; Margotti M; Santoro R; Piazzolla V; Brunetto MR; Coco B; Cavallone D; Zhao Y; Joshi A; Woo J; Lau AH; Gaggar A; Subramanian GM; Massetto B; Fung S; Ahn SH; Ma X; Mangia A; Ferrari C
Gastroenterology; 2019 Jul; 157(1):227-241.e7. PubMed ID: 30930022
[TBL] [Abstract][Full Text] [Related]
37. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
Heathcote EJ; Marcellin P; Buti M; Gane E; De Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Gurel S; Snow-Lampart A; Borroto-Esoda K; Mondou E; Anderson J; Sorbel J; Rousseau F
Gastroenterology; 2011 Jan; 140(1):132-43. PubMed ID: 20955704
[TBL] [Abstract][Full Text] [Related]
38. A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients.
Kayaaslan B; Akinci E; Ari A; Tufan ZK; Alpat SN; Gunal O; Tosun S; Guner R; Tabak F
Clin Res Hepatol Gastroenterol; 2018 Feb; 42(1):40-47. PubMed ID: 28757048
[TBL] [Abstract][Full Text] [Related]
39. Baracle
Kim DY; Kim JH; Tak WY; Yeon JE; Lee JH; Yoon JH; Lee YJ; Lee BS; Han BH; Lee HC
Drug Des Devel Ther; 2017; 11():3145-3152. PubMed ID: 29184389
[TBL] [Abstract][Full Text] [Related]
40. Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load.
Pan CQ; Duan Z; Dai E; Zhang S; Han G; Wang Y; Zhang H; Zou H; Zhu B; Zhao W; Jiang H;
N Engl J Med; 2016 Jun; 374(24):2324-34. PubMed ID: 27305192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
